Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 382 clinical trials
Featured trial
Non-Muscle Invasive Bladder Cancer BOND-003

People with Non-Muscle Invasive Bladder Cancer are asked to participate in a research study being conducted by Montefiore Medical Center. 

invasive bladder cancer
radical cystectomy
bladder tumor
  • 0 views
  • 03 Aug, 2021
  • 1 location
Featured trial
A Study to Evaluate INSTILADRIN® in Patients With High Grade, Bacillus Calmette-Guerin (BCG) Unresponsive NMIBC- Non muscle invasive bladder cancer

A Study to Evaluate INSTILADRIN® in Patients With High Grade, Bacillus Calmette-Guerin (BCG) Unresponsive NMIBC- Non muscle invasive bladder cancer

  • 142 views
  • 08 Nov, 2020
  • 1 location
Featured trial
A multicenter clinical study of the Sonablate® 500 (Sonablate) for the TreAtment of locally Recurrent prostate cancer with HIFU(STAR Trial)

A multicenter clinical study of the Sonablate® 500 (Sonablate) for the TreAtment of locally Recurrent prostate cancer with HIFU(STAR Trial)

  • 229 views
  • 25 Mar, 2021
  • 1 location
A Study of Atezolizumab Versus Placebo as Adjuvant Therapy in Patients With High-Risk Muscle-Invasive Bladder Cancer Who Are ctDNA Positive Following Cystectomy (IMvigor011)

This is a global Phase III, randomized, placebo-controlled, double-blind study designed to evaluate the efficacy and safety of adjuvant treatment with atezolizumab compared with placebo in participants with MIBC who are ctDNA positive and are at high risk for recurrence following cystectomy.

  • 0 views
  • 29 Apr, 2022
  • 160 locations
Atezolizumab Plus One-year BCG Bladder Instillation in BCG-naive High-risk Non-muscle Invasive Bladder Cancer Patients

This is an open-label, randomized, multicentric study in patients with high-risk non-muscle invasive bladder cancer who had never received BCG for this disease. The objective is to

intravesical administration
transurethral resection
bladder instillation
carcinoma
neutrophil count
  • 34 views
  • 07 Apr, 2021
  • 30 locations
Atezolizumab and BCG in High Risk BCG naïve Non-muscle Invasive Bladder Cancer (NMIBC) Patients (BladderGATE) (BladderGATE)

Patients with high-risk non-muscle invasive bladder cancer (NMIBC) are usually managed by transurethral resection of their bladder tumor (TURBT) alone plus additional intravesical therapy to

carcinoma in situ
bladder cancer
transurethral resection
carcinoma
tumor cells
  • 0 views
  • 21 Mar, 2022
Study Evaluating the Efficacy and Safety of Multiple Immunotherapy-Based Treatments and Combinations in Patients With Urothelial Carcinoma (MORPHEUS-UC)

A Phase Ib/II, open-label, multicenter, randomized, umbrella study in participants with MIBC and in participants with locally advanced or metastatic Urothelial Carcinoma (UC) who have progressed during or following a platinum-containing regimen. The study is designed with the flexibility to open new treatment arms as new treatments become available, close …

metastatic urothelial carcinoma
combinations
carcinoma
gemcitabine
measurable disease
  • 13 views
  • 13 May, 2022
  • 32 locations
A Study of Enfortumab Vedotin Alone or With Other Therapies for Treatment of Urothelial Cancer (EV-103)

to treat patients with cancer of the urinary system (urothelial cancer). This type of cancer includes cancer of the bladder, renal pelvis, ureter or urethra. Some parts of the study will look at

metastatic urothelial carcinoma
transurethral resection
enfortumab vedotin
radical cystectomy
metastasis
  • 316 views
  • 21 Apr, 2022
  • 105 locations
Bempegaldesleukin and Pembrolizumab With or Without Chemotherapy in Locally Advanced or Metastatic Solid Tumors (PROPEL)

This study is to assess the safety and tolerability, and to assess the preliminary clinical benefit of NKTR-214 when combined with pembrolizumab (KEYTRUDA®) with or without chemotherapy. The study is comprised of two groups; dose optimization and dose expansion cohorts. Dose Optimization included first-line and second-line advanced or metastatic solid …

metastatic urothelial carcinoma
growth factor
EGFR
immunomodulators
squamous cell carcinoma
  • 1698 views
  • 19 Apr, 2022
  • 24 locations
Neoadjuvant Atezolizumab in Localized Bladder Cancer

This phase II trial studies the best dose of atezolizumab in treating patients with bladder cancer that has not spread to other places in the body. Immunotherapy with monoclonal antibodies may

radical cystectomy
white blood cell count
neutrophil count
metastasis
gilbert's syndrome
  • 8 views
  • 19 Apr, 2022
  • 1 location